Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine

Urology

Volumn 60, Issue 6, 2002, Pages 1111vi-1111ix

  Morris, Michael J ^a   Santamauro, Jean ^a   Shia, Jinru ^a   Schwartz, Lawrence ^a   Vander Els, Nicholas ^a   Kelly, Kevin ^a   Scher, Howard ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; ESTRAMUSTINE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG FATALITY; HUMAN; HUMAN TISSUE; LUNG EXAMINATION; LUNG TOXICITY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RESPIRATORY FAILURE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; FATAL OUTCOME; HUMANS; MALE; PACLITAXEL; PROSTATIC NEOPLASMS; RESPIRATORY INSUFFICIENCY; TAXOIDS;

EID: 0036899952     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01921-0     Document Type: Article

References (16)

1. Petrylak D.P., Macarthur R.B., O'Connor J., et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 17:1999;958-967.
2. Kreis W., Budman D.R., Fetten J., et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 10:1999;33-38.
3. Savarese D.M., Halabi S., Hars V., et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer a final report of CALGB 9780. J Clin Oncol. 19:2001;2509-2516.
4. Natale R.B., Zaretsky S.L. Phase I/II trial of estramustine (E) and Taxotere (T) in patients with metastatic hormone-refractory prostate cancer (HRPC). (abstract) Proc Am Soc Clin Oncol. 18:1999;348a.
5. Kosty M.P., Ferreira A., Bryntesen T., et al. Weekly docetaxel and low-dose estramustine phosphate in hormone refractory prostate cancer a phase II study. (abstract) Proc Am Soc Clin Oncol. 19:2000;365a.
6. Copur M.S., Ledakis P., Lynch J., et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol. 28:(suppl 15):2001;16-21.
7. Picus J., Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer preliminary results. Semin Oncol. 26:(suppl 17):1999;14-18.
8. Read W.L., Mortimer J.E., Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 94:2002;847-853.
9. Product Information: Taxotere™, Docetaxel. Collegeville, Pennsylvania, Rhone-Poulenc Rorer Pharmaceuticals Inc., 1999.
10. Berry W., Dakhil S., Gregurich M.A., et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 28:(suppl 15):2001;8-15.
11. Zulian G.B., Aapro M.S. Docetaxel and radiation-recall severe mucositis. Ann Oncol. 5:1994;964.
12. Camidge D.R., Kunkler I.H. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence. Clin Oncol (R Coll Radiol). 12:2000;272-273.
13. Kunitoh H., Watanabe K., Onoshi T., et al. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer a Japanese cooperative study. J Clin Oncol. 14:1996;1649-1655.
14. Merad M., Le Cesne A., Baldeyrou P., et al. Docetaxel and interstitial pulmonary injury. Ann Oncol. 8:1997;191-194.
15. Etienne B., Perol M., Nesme P., et al. Acute diffuse interstitial pneumopathy following docetaxel (Taxotere) apropos of 2 cases. Rev Mal Respir. 15:1998;199-203.
16. Wang G.S., Yang K.Y., Perng R.P. Life-threatening hypersensitivity pneumonitis induced by docetaxel (Taxotere). Br J Cancer. 85:2001;1247-1250.